#1evotec Driving growth & Getting ready for launch Evotec SE, H1 2021 Interim Report, 11 August 2021 #RESEARCHNEVERSTOPS 00 11111101001 00#2PAGE 1 evotec Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goal", "intend", "look forward to", "may", "plan", "potential", "predict", "project", "should", "will", "would" and similar expressions. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this presentation. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements. Note: The operating business of Evotec GT commenced on 1 April 2020. In addition, the acquisition of the assets (mainly land and buildings) and the takeover of employees of the Biopark by Sanofi SAS in Toulouse became legally effective on 1 July 2020. The two entities were fully consolidated in the consolidated financial statements from the dates specified above.#3evotec Werner Lanthaler¹) CEO PAGE 2 Welcome to H1 2021 The Management Team Enno Spillner¹) CFO 1) On the call for the H1 2021 interim report Craig Johnstone COO Cord Dohrmann CSO#4PAGE 3 evotec Agenda Highlights Financial performance H1 2021 "Building for growth" Guidance 2021#5evotec SMALL MOLECULES BIOLOGICS PAGE 4 DRUG DISCOVERY PLATFORM CELL & GENE THERAPY PRECLINICAL 33 ANTIS THERAPY FROPULT DISCOVERY Strong overall performance and progress in all "lanes" H1 2021 - Highlights & Lowlights Highlights • Business building accelerated, despite COVID-19 Multiple new & extended integrated drug discovery and development alliances (EVOIR&D) • J.PODⓇ 1 US in Redmond opening August 18th; construction of J.POD® 2 EU to start in Q4 2021 (EVOaccess) Acquisition of Verona site completed - Now "Campus Levi-Montalcini" BMS Oncology protein degradation partnership – significant extension ahead of term • New protein degradation collaboration in undisclosed therapeutic area also signed with BMS PRROTECT, an initiative for pandemic preparedness, launched • Confidential submission of draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed offering of American Depositary Shares (after period-end) • Positive Phase Ilb results for Bayer's eliapixant in patients with refractory chronic cough (RCC) (after period-end) (EVOroyalty) Lowlights Slight delays in milestones, but several important milestones imminent#6● evotec Strong overall performance Fully in line with strategy - investments for long-term growth Financials H1 2021 & FY 2021 Guidance Group revenues increase by 17% to € 271.3 m (H1 2020: € 231.0 m). Organic growth at record level of 27% Adjusted Group EBITDA¹) of € 36.2 m (H1 2020: € 47.3 m) mainly affected by planned capacity build-up ahead of imminent production start of J.PODⓇ 1 US. Like-for-like growth 13% • Increase of expenses for unpartnered R&D by 29% to € 27.8 m (H1 2020: € 21.6 m) PAGE 5 Despite high investments in new J.PODⓇ 1 US and other capacity expansions, Net debt leverage ratio remains at even negative level -1.0 x adjusted EBITDA excl. IFRS 16 Confirmation of 2021 outlook & Action Plan 2025 ambitions Group revenues € 550 - 570 m (2020: € 500.9 m) Adjusted Group EBITDA € 105 -120 m (2020: € 106.6 m) Unpartnered R&D € 50 - 60 m (2020: € 46.4 m) • Action Plan 2025 targets confirmed: Revenues > € 1,000 m, adjusted EBITDA > € 300 m, unpartnered R&D > € 100 m ¹) Before contingent considerations, income from bargain purchase & excluding impairments on goodwill, other intangible & tangible assets as well as the total non-operating result#7evotec Evotec's integrated platforms R&D efficiency platforms¹) PAGE 6 1101100 01110 1101101001 00 Y Our innovation hub addresses the industry's needs Leadership in efficiency, data, science, multimodality and access Precision medicine platforms Just- Evotec Biologics¹) - Multimodality drug design Fully integrated AI/ML-driven drug discovery & development platforms Industrial scale Omics and ¡PSC platforms AI/ML powered disruptive biologics discovery and manufacturing platforms Small molecules, biologics, iPSC-based cell therapy, emerging gene therapy toolbox ¹) Also partly accessible as stand alone "Fee-for-service" or FTE rates-based offerings 2) "Fee-for-service" also encompasses FTE rates-based collaborations EVOIR&D EVOpanOmics & EVOpanHunter EVO access EVOcells & EVOgenes Core collaboration routes 0-0 "Fee-for-service❞2) EVO equity EVOroyalty#8evotec Industry needs PAGE 7 0110110001 0111000 110101010011 00 Y R&D efficiency platforms¹) Precision medicine platforms Just - Evotec Biologics¹) Multimodality drug design Stand-alone & integrated offerings see strong demand Examples of capabilities & expertise overview Capabilities & expertise (illustrative) Target ID & validation EVOpanOmics 18% Hit identification EVOcells Sample management EVOpanHunter EVOgenes A TM D O E M J.DISCOVERY J.HALM MOLECULE DISCOVERY DMPK & ADME-Tox Research Informatics iPSC platform SM V Antibodies & Bifunctionals AI DESIGNED MAB LIBRARY Bio Reagents ¹) Also partly accessible as stand alone "Fee for Service" or FTE-rate based offerings Small molecules In vitro biology ScreenSeq™M J.MD TM In vivo Pharmacology MOLECULE DESIGN 60 000 Antisense Biomarker discovery 18 Integrated CMC Protein degradation JP3Ⓡ PROCESS & PRODUCT DESIGN ScreenPepTM J.HALM fo Lead optimisation INDIGO Exosomes AI DESIGNED MAB LIBRARY J.PODⓇ G MANUFACTURING DESIGN RNA#9PAGE 8 evotec Agenda Highlights Financial performance H1 2021 "Building for growth" Guidance 2021#10in € m¹) evotec Revenues from contracts with customers Gross margin Strong growth & investments into capacity, R&D, and SG&A Condensed income statement H1 2021 – Evotec SE and subsidiaries R&D expenses • SG&A expenses • Impairment of intangible assets and goodwill • Other op. income (expenses), net Operating result Adjusted Group EBITDA²) Net income PAGE 9 H1 2021 271.3 20.8% (35.4) (46.4) (0.7) 34.5 8.3 36.2 112.7 H1 2020 231.0 23.0% (29.8) (36.5) 32.2 18.9 47.3 7.3 Change 17% 19% 27% 7% (56)% (23)% >>>100% • Revenue growth 17% (27%, adjusted for portfolio & fx effects) • R&D expenses up 19% as planned • SG&A up 27% as planned due to upscaling and depreciation, plus final ramp-up J.PODⓇ 1 US ahead of opening Adj. EBITDA like-for-like growth 13% despite higher R&D and SG&A • Net income benefits from fair value adjustment of EVO equity investment Exscientia ¹) Differences may occur due to rounding 2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result 3) Sanofi payment Q1 2020#11evotec Revenues from contracts with customers (in € m) Base revenues Milestones, upfronts and licences PAGE 10 231.0 7.8 223.2 H1 2020 +17% +17% Gross margin affected by ongoing capacity build-up - as planned Revenues & Gross margin overview - Evotec SE and subsidiaries 271.3 10.0 261.3 H1 2021 Gross margin (in %) Total Margin Margin excl. milestones, upfronts and licences and amortisation 23.0 23.4 H1 2020 20.8 19.4 H1 2021 • Base revenues up 17% or € 38.1 m to € 261.3 m. Adjusted for anticipated end of Sanofi subsidy and unfavourable fx effects growth would have reached 22% • Just - Evotec Biologics added revenues of € 23.0 m, increase of 44% Despite higher year-on-year milestone revenues of € 4.1 m (H1 2020: € 2.2 m), some milestone payments still delayed due to COVID-19, but imminent • Gross margin decreased mainly due to capacity build-up ahead of launch of J.PODⓇ 1 US in Q3 and fx#12in € m¹) evotec Revenues PAGE 11 Strong performance across all business lines Segment information H1 2021- Evotec SE and subsidiaries Gross margin • R&D expenses • SG&A expenses Impairment of intangible assets and goodwill • Other op. income (expenses), net Operating result Adjusted EBITDA²) Inter- EVT EVT segment Execute Innovate elimination 279.5 57.3 (65.5) 19.0% (1.0) (37.2) 11.4 26.2 51.9 16.3% (40.5) (9.2) (0.7) 23.2 (17.9) (15.7) 6.0 T Evotec Group 271.3 20.8% (35.4) (46.4) (0.7) 34.5 8.3 36.2 . Both segments show very strong performance versus Q1 • EVT Execute: 18% growth including inter- segment revenues implies accelerated demand for integrated offering EVOIR&D; 15% growth of external revenues driven by strong base business demand • EVT Innovate: 27% growth driven by precision medicine platforms Adjusted Group EBITDA influenced by end of Sanofi subsidy, unfavourable fx effects, increased R&D investments and planned capacity expansion, reflected by growing SG&A ¹) Differences may occur due to rounding 2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result#13in € m evotec 231.0 222.4 -8.6 M Portfolio¹) Revenue H1 Organic growth 2020 excl. portfolio¹) Revenues H1 2020 PAGE 12 Growth acceleration continues in second quarter Revenue bridge H1 2020 - H1 2021 - Evotec SE and subsidiaries ¹) Sanofi payment Q1 2020 -11.5 60.4 fx effect 271.3 Revenues H1 2021 • 17% growth of Group revenues • fx effect: € (11.5) m (-5%) Organic growth of € 60.4 m translates in record growth rate of 27%, driven by base business and in particular strong demand for EVOIR&D offering ● Organic growth reached 28% in Q2 after 26% in Q1#14PAGE 13 evotec Well-balanced global customer mix further improving Selected KPIs H1 2021 Revenue by customer type YTD¹) in % (H1 2021) Mid-sized Pharma Foundation/ NFP/Academic Biotech Top 20 Pharma 1) Third-party revenues only 14% 9% 41% 36% H1 2021 100% Revenues by region YTD¹) in % (H1 2021) Rest of World USA Europe 4% 53% 43% H1 2021 100%#15in € m evotec PAGE 14 47.3 EBITDA H1 2020 -8.6 Portfolio¹) Double-digit organic EBITDA growth year-on-year EBITDA bridge H1 2020 - H1 2021 - Evotec SE and subsidiaries 38.6 EBITDA Q2 2020 excl. portfolio¹) ¹) Sanofi payment Q1 2020 5.0 Organic growth -7.4 fx effect 36.2 EBITDA H1 2021 • Pure organic growth of adjusted EBITDA in H1 reached 13% • fx effect of € 7.4 m amounts to -19% • Decrease of 23% mainly due to delay of milestones as well as planned investments at all functional levels securing growth and capacity#16in € m¹) evotec Revenues from contracts with customers Gross margin ● R&D expenses • SG&A expenses Impairment of intangible assets Impairment of goodwill • Other op. income (expenses), net Operating result Adjusted Group EBITDA²) Capacity build-up temporarily affects margin Condensed income statement Q2 2021 - Evotec SE and subsidiaries Net income PAGE 15 Q2 2021 138.2 18.5% (17.0) (25.2) (0.7) 18.8 1.5 15.1 60.0 Q2 2020 111.6 17.7% (14.7) (19.3) 17.0 2.8 17.3 (9.8) • Base revenues accelerated in Q2 versus Q1 2021 across all business lines while fx headwinds • R&D investments higher - as planned • SG&A reflects further dynamic growth and strategic projects • As a result EBITDA slightly below previous year level EVO equity: Net Income benefits from 2nd fair value adjustment in 2021 of Exscientia investment ¹) Differences may occur due to rounding 2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result#17evotec Balance sheet total in € m 1,462.9 (1.5). PAGE 16 Strong balance sheet supporting accelerated growth Balance sheet and liquidity – 31 Dec. 2020 vs. 30 June 2021¹) – Evotec SE and subsidiaries Net Debt ratio (excl. IFRS 16) x adjusted EBITDA²) Equity Ratio in % 1,621.1 49.4 49.4... Liquidity position in € m (1.0) 481.9 ¹) Differences may occur due to rounding 2) Versus 31 Dec 2020; incl. IFRS16 0,1 (31 Dec 2020) vs 0,7 (30 June 2021) 52.6 449.3 • Total assets, liabilities and equity increased by around 11% Equity ratio again increased by 3.2 percentage points With cash spend in first quarter, net debt leverage ratio remains very comfortable at -1.0 x adjusted EBITDA excl. IFRS 16 • While strong operating cash flow, liquidity decreased € 33 m from investments for J.POD® 1 US, capex for growth and continued EVO equity engagements#18PAGE 17 evotec Agenda Highlights Financial performance H1 2021 "Building for growth" Guidance 2021#19PAGE 18 evotec Record demand - Capacity expansion around the globe Expansion of footprint at all sites France - "Campus Curie" J.PODⓇ 2 EU initiated Italy - Verona Acquisition of Verona site from GlaxoSmithKline SpA - Now "Campus Levi-Montalcini" Germany - Hamburg, Goettingen - "Manfred Eigen Campus", Munich, Cologne New building initiated for "The lighthouse of iPSC" in Hamburg; expansion in Munich and Goettingen UK - Abingdon - "Dorothy Crowfoot Hodgkin Campus", Manchester Dorothy Crowfoot Hodgkin Campus and Manchester expansion USA - Branford, Princeton, Redmond, Seattle, Watertown . All sites ready for expansion • J.PODⓇ 1 US operational start in Q4 2021 Austria - Orth Footprint expansion under evaluation.#20evotec Rita Levi-Montalcini PAGE 19 Campus Levi-Montalcini creates long-term growth opportunities "Campus Levi-Montalcini" - Acquisition of the Verona site from GlaxoSmithKline SpA FUTURE evotec CAMPUS LEVI-MONTALCINI MADAR evotec Erd PREXIMA 80 Ownership improves flexibility Acquisition from GSK strengthens fully integrated R&D solutions for partners ● • 75,000 m² of state-of-the-art scientific and tertiary facilities plus 38,000 m² plot Currently ~ 750 employees in Verona with space to further grow following Action Plan 2025 • "Campus Levi-Montalcini" in commemoration of Italian Nobel laureate Rita-Levi Montalcini Rita Levi-Montalcini, (22. April 1909 - 30. December 2012); Italian Nobel laureate, honored for her work in neurobiology (1986) (Wikipedia)#21evotec Aerial view of new location in Redmond, Washington, US CELL EXPANSION PAGE 20 J.POD® 1 in US - Grand opening on 18th of August State-of-the-art manufacturing facility for biologics our mission design and apply innovative technologies to dramatically expand global access to biotherapeutics 21 2-UF-301 JPOD Labd • 12,077 m² development and commercial production site • Certificate of Occupancy in May (employees on site) • Cost effective and flexible. Intensified production processes are run inside autonomous cleanrooms that can be reconfigured; qualification activities underway • Production from a few kilograms to metric tons in the same facility • Initially operational in Q4 2021#22PAGE 21 evotec New manufacturing options to avoid biologics shortage in EU Campus Curie home for new J.POD® showcases next-generation options Europe is second-largest market for biologics; local capacities to secure supply urgently needed • J.POD® 2 EU creates operational efficiency and capacity for biological treatments in EU ● Strong support from French government, Occitanie region, Bpifrance, Haute-Garonne prefecture as well as Toulouse Métropole ● Two hectares of land¹) at Campus Curie already identified and design plan started Opportunity to build global J.PODⓇ network ¹) Dependent of local plannings, environmental and building requirements as well as further conditions evotec NEWS RELEASE, 20 APRIL 2021 #RESEARCHNEVERSTOPS EVOTEC ACCELERATES ACCESS TO BIOLOGIC THERAPEUTICS WITH INITIATION OF MANUFACTURING FACILITY IN TOULOUSE ► J.POD 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19 ▸ EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE CONSTRUCTION OF THE J.POD 2 EU FACILITY TO START IN H2 2021 Hamburg, Germany, 20 April 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. J.POD 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. J.POD® 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's first J.POD® 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021. With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the United States Department of Defense. In addition to J.POD technology, Evotec is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents. For further information, please contact: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing. [email protected], T. +49(0)40.560 81-255, F. +49(0)40.560 81-333, www.evotec.com#23Clinical Preclinical Discovery evotec PAGE 22 Ph3 Ph2 Ph1 Insomnia CC - P2X3 ND ND ALS ND ND 12 ND 11 ND 10 ND 9 ND 8 ND 7 ND 6 ND 5 ND 4 ND 3 ND 2 ND 1 Partnered Pipeline Neuroscience & Pain NP-P2X3 Pain ND ND 14 LDD 3 LDD 2 LDD 1 OAB-P2X3 ND 15 EVT Glaucoma EVT Fragile X EVT Canavan EVT Gaucher EVT RPE-P EVT iPSC Myelin EVT iPSC- ICT The iceberg of co-owned product opportunities is growing In total > 200 projects with big financial upside Cajal Neurosciences Aeovian ND Facio FSHD 1 Facio FSHD 2 Exscientia Psychiatry Exscientia ND 1 LAB282 N=3 Breast cancer EVT iPSC Dir. Diff. LAB150 N=1 Unpartnered Pipeline A2A EVT 801 10 LDD 5 LDD 4 Onco 4 Onco 3 Onco 2 Onco 1 EVT TargetFAP EVT FF-Ab 2 EVT FF-Ab 1 EVT MDSC-screen EVT/MF AlloMod 3 EVT/MF AlloMod 2 EVT/TMF AlloMod 1 Oncology EVT LAB301 4 EVT LAB301 3 EVT LAB301 2 EVT LAB301 1 EVT iTab EVT iM EVT iTgd EVT INK EVT/Indiv Lung c 3 EVT/Indiv Lung c 2 EVT/Indiv Lung c 1 Equity Pipeline EVT act EVT Ice EVT ObliTaim Carrick Breast Cancer Carrick CRPC Carrick TNBC Exscientia ND 2 Exscientia ND 3 Immunitas solid and hemat Immunitas IMT-073 Exscientia ND 4 Quantro ND Breakpoint ND 2 Breakpoint ND 1 Blacksmith ND Exscientia 101 Exscientia 102 Exscientia N=5 DarkBlue Therapeutics Autobahn Labs Immunitas ND OxVax LAB150 N=1 Metabolic Diseases ND 10 ND 9 ND 8 ND 7 ND 6 ND 5 ND 4 ND 3 ND 2 ND 1 Fibrosis LDD 7 LAB282 N=7 BRIDGES Pipeline LDD 6 QRbeta Encapsß EVT S460 QRbeta iBeta EVT Fibr. IBD 2 EVT Fibr. IBD 1 EVT TargetTF CDK/fibrosis EVT TargetTF Fibrosis EVT iCardiomyocyte EVT NephSyn EVT Nurture EVT QUOD EVT Neplex EVT HPP EVT Nurture TID 1 Eternygen NASH/Diabetes Neph Thera ND Topas T1D Topas PV LAB150 N=1 LAB282 N=2 EVT Nurture TID 4 EVT Nurture TID 3 EVT Nurture TID 2 *Also includes Women's Health, Respiratory projects The Equity Pipeline does not contain programs from EVT/partners that are not publically disclosed Inflammation & Immunology* Endo - P2X3 Endo ND 8 ND 8 ND 7 ND 6 ND 5 ND 4 ND 3 ND 2 ND 1 EVT ILR-23 Endo P2X7 Fibrocor IPF Topas Anti-drug IR Topas ND 2 Topas ND 1 Blacksmith ND Celmatix OS Celmatix PCOS Fibrocor Fibrosis Fibrocor CA Nephropathy Exscientia Respiratory Exscientia N=5 CureXsys ND Topas Pemphis vulgaris Topas Celiac disease Exscientia ND 5 LAB150 N=2 LAB282 N=5 Topas Uveitis/Cholangiti Virology HBV Covid-19 3 HBV-HBX HBV RNA HBV-HBc EBV 2 EBV 1 Flu 2 Flu 1 BKV Exscientia Covid-19 LAB282 N=2 Anti-bacterial Noso-502 Naphtamidine S Neopyrrolomy cins Tribe Carb-X Noso-2G Cystobactamid eAMR Staph persist RNA Pol HDT VMM Forge LpxC UTI Forge LpxC Lung Forge LpxC STD Forge DXR Forge IspF Forge RNAP Forge ThrS Forge ND Exscientia ND 6 LAB282 N=2 Global Health CHIK-V Malaria AP series Resorcinomyci n TB HTS TB Whole Cell HTS Natural product TB patDB Product screen#24evotec Proteomics approach to targeted protein degradation Development of novel therapies for a broad range of diseases Opportunity to expand and accelerate with AI/ML PAGE 23 Protein degradation partnership extended and expanded Alliance with BMS since 2018 - already proven to be highly productive evotec & & ll Bristol Myers Squibb May 2020 First screening milestone Oct 2020 First project initiation 2018 Upfront US$ 65 m • Potential milestones 2019 > US$ 250 m per project • Double-digit royalties 2020 June 2020 US$ 10 m - Expansion New Mar 2021 Significant double-digit m extension Dec 2020 Second project initiation New June 2021 New protein degradation collaboration in undis- closed therapeutic area 2021 New May 2021 Third project initiation#25evotec "Evotec Inside" Fully invested pipeline gaining visibility Progress of drug candidates in advanced stages Selected pipeline events within next 18 - 24 months • Phase III data (China) with JingXin in insomnia • Phase Ilb data with Bayer in RCC (eliapixant) • Phase II data with Bayer in Overactive bladder (eliapixant) • Phase II with Bayer in Endometriosis (eliapixant) • Phase II with Bayer in Neuropathic pain (eliapixant) Phase II with Bayer in Gynaecology (B1 antagonist) • Phase I data in Chikungunya virus Phase I initiation with BMS in CNS • Phase I data with Exscientia in Oncology (A2a) • Phase I initiation with Kazia in Oncology (EVT801) Phase I with Sanofi in HBV PAGE 24 Multiple co-owned equity companies will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...) Clinical Pre-clinical Discovery Molecule EVT201 BAY-1817080 Therapeutic Area/Indication Insomnia (GABA-A) Chronic cough (P2X3) BAY-1817080 Overactive bladder BAY-1817080 Neuropathic pain BAY-1817080 Endometriosis CT7001 CT7001 EVT401 BAYXXX BAY2328065 BI 894416 BI 860585 TPM203 DSP-1181 CNTX 6016 EVT894 BAYXXX EVT801 APN411 EXS21546 GLPGXXXX BAYXXXX QRB001 BMSXXXX EVT895 EVTXXXX Oncology (CDK7) Oncology (CDK7) Immunology & Inflammation (P2X7) Women's health Gynaecology Asthma (not disclosed) Oncology (mTORC1/2) Pemphigus Vulgaris (not disclosed) Obessive-compulsive disorder (5-HT1A) Pain (CB2) Chikungunya (Antibody) Endometriosis (not disclosed) Oncology (VEGFR3) Oncology - Immunotherapy Oncology (various programmes) Fibrosis (not disclosed) Nephrology (not disclosed) Metabolic Diabetes (not disclosed) Neurodegeneration (not disclosed) HBV CNS, Metabolic, Pain ... Partner 入京新药业 INGAN PHARMACEUTICAL Carrick 12 occutics Carrick 12occutics 克斯坦奥集团 CONEA GROUP BAYER Boehringer Ingelheim Boehringer Ingelheim Topas Therapeutics Exscientia Boehringer Ingelheim NIH SANOFI SANOFI SIOLOGICS SANOFI APEIRON Exscientia Galápagos QRbeta THE RAFELTICS Bristol Myers Squibb SANOFI >10 further programmes Discovery Pre-clinical Phase I Phase II Multiple programs across nephrology, oncology, immunology among other therapeutic areas Phase III#26evotec Positive outcome of Phase IIb trial (PAGANINI) Statistically significant improvement in 24-hour cough counts per hour over placebo after 12 weeks of treatment²) • Positive outcome in chronic cough regarding efficacy, safety and differentiation³) • Favourable safety and tolerability profile PAGE 25 Positive Phase IIb headline data supports best-in-class potential P2X3 antagonist - eliapixant (BAY1817080) Refractory Chronic Cough (RCC) Cough frequency in Phase lla¹) Mean relative change in hourly cough frequency assessed over 24-hour periods versus placebo Mean relative change in cough frequency versus placebo (%) 35 25 15 5 -5 -15 -25 -35 10% -45 -15% 10 mg p=0.004 200 mg BAY 1817080 dose Vertical lines show 90% credible limits. Duration of treatment was 1 week with each dose of BAY 1817080. -23% 50 mg -25% p=0.002 750 mg Detailed efficacy and safety data will be presented by Bayer at upcoming scientific congress 1) Sources: https://conference.thoracic.org/ Poster presented on the ATS 2020 International Conference Virtual Platform 2) Average hourly cough frequency based on 24-hour sound recordings 3) Source: https://media.bayer.com/baynews/baynews.nsf/id/A3224676255E5482C125872600261CAE?open&ref=irrefndcd RCC* Multiple indications potential Overactive Bladder Others BAYER BAYER Endometriosis neuropathic ... pain,#27PAGE 26 evotec PRROtect Lessons from COVID-19 Building a unique pandemic Preparedness and Rapid Response TEChnology Platform @g 河 感#28PAGE 27 evotec Welcome back, Kara! Kara Carter re-joining Evotec to strengthen Evotec's position in Virology "Chronic Hepatitis B continues to have a tremendous burden on global health. Finding a cure for this disease requires innovative approaches and is critically important to improving the health of millions of patients world wide." Kara Carter#29PAGE 28 evotec Keeping the promise ESG & Sustainability - Measures taken in H1 2021 Responsible use of resources • Sourcing of 100% renewable energy since January 2021 at all German sites • Decision on replacement of heating system in building B95 in Abingdon (estimated savings of CO₂e of ~800t per year as of Q2 2022) ESG topics part of our DNA Group-wide inclusion of ESG topics in personal 2021 targets of all employees • Definition of responsibilities for delivering expanded set of sustainability KPIs Group-wide appreciation & celebration of Diversity weeks in May and pride month in June Intensified stakeholder dialogue Increasing awareness and appreciation of investors and rating agencies • MSCI ESG rating up from BBB to A as of January 2021 • ISS ESG rating up from C- to C as of May 2021#30evotec Basic Research PAGE 29 Funding Level LAB282 Oxford 37 active / completed projects Initiated 2016 ts LAB150 Toronto 10 active / completed projects Initiated 2017 BRIDGES bring multiple future investment options Creating long-term optionality with efficient translation Applied Research LAB031 France a 5 active / completed In projects. Sanofi collaboration Initiated 2018 or's Technology Development and Demonstration AUTOBAHN LABS US West Coast 2 active / completed projects Initiated 2020 to DANUBE LABS Europe New launch with Cebina Initiated 2021 New Product Commercialisation and Market Development ARGOBIO STUDIO Europe >20 projects evaluated. Start-up studio Initiated 2021 te te New beLAB2122 Germany New strategic partnership. BMS collaboration Initiated 2021 BUK adı Market Entry & Market Volume New Public Market Pension Plan beLAB1407 New strategic partnership. BMS collaboration Initiated 2021 New#31evotec At equity investments (share ≥ 20% or significant influence) facio therapies Eternygen Equity participation Metabolic disorders Initiated 2016 Carrick PAGE 30 therapeutics Equity participation Innovative pathways in oncology Initiated 2016 Topas Therapeutics Spin-off Nanoparticle- based therapeutics Minority Shareholdings (share < 20%) Initiated 2016 Exscientia Equity participation Al for auto- mated drug design Initiated 2017 Equity participation FSHD Growing portfolio with operational synergies EVOequity overview Initiated 2017 FORGE Therapeutics Equity participation Targeting metallo- enzymes Initiated 2017 AUTOBAHN LABS Equity (in-kind) Cross therapeutic areas Initiated 2019 FIBROCOR Equity participation Fibrosis partnership Initiated 2017 BREAKPOINT THERAPEUTICS Spin-off DNA damage response Initiated 2019 Aeovian PHARMACEUTICALS Initiated 2019 Equity participation Women's health celmatix® Initiated 2019 Equity Equity participation participation Inflammatory disease Immunitas THERAPEUTICS Oncology / Biologics Initiated 2019 CUREXSYS PURE TO CURE Equity participation Cross therapeutic areas Initiated 2020 BLACKSMITH Medicines DARK BLUE Initiated 2019 THERAPEUTICS Spin-off (LAB282) Oncology Initiated 2020 LEON ENABLING NANO NOW Equity Equity participation participation Oncology Formulation nanotech- nologies Initiated 2020 Equity participation Failsafe cloaking for cell therapies mission BIOCAPITAL Venture fund Invests into early-stage life science companies a Initiated 2020 panCELLa Initiated 2020 Cajal Neuroscience Equity participation Neuro-science Initiated 2020 QUANTR !!~ and Therapeutics Equity participation partnership Oncology Initiated 2020 oxvax Equity participation Immuno- oncology Initiated 2021 Joint Venture New NephThera Joint Venture with Vifor Pharma Nephrology Initiated 2019 ARGOBIO STUDIO Equity participation Cros therapeutic areas Initiated 2021 New#32PAGE 31 evotec Agenda Highlights Financial performance H1 2021 "Building for growth" Guidance 2021#33evotec میرا PAGE 32 Strong year ahead Guidance 2021 Very good top-line growth expected Assumption based on current orders, prospective milestone payments • Total Group revenues € 550-570 m (€ 565-585 m at constant exchange rates¹)) EBITDA guidance confirmed - despite massive investments Expanding scope of strategic investments for promising R&D projects, ramp-up of Just - Evotec Biologics business, expansion of J.PODⓇ 1 US capacities in US & J.POD® 2 EU Adjusted Group EBITDA²) € 105-120 m (€ 115-130 m at constant exchange rates ¹)) Accelerated R&D investments for growth • Further expand long-term & sustainable pipeline of first-in-class projects & platforms Unpartnered Group R&D expenses of € 50-60 m³) ¹) $/ € 2020: 1.15; €/GBP 2020: 1.13 2) Before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result 3) Evotec focuses its guidance and upcoming reporting on the "unpartnered R&D" part. ID-related R&D expenses will be fully reimbursed its partner Sanofi ("partnered R&D").#34PAGE 33 evotec 00 11111101001 ON [ Our mid-term aspirations are ..just the beginning" 2020-2025e Key Performance Indicator goals ¹) before significant royalties 2) incl. Equity participations Revenues in € m 500.9 >100% Unpartnered R&D in € m 46.4 >1,000 106.6 >100% Adjusted EBITDA¹) in € m >100 ≥180% Co-owned projects²) 118 >100% ≥300 >250#35PAGE 34 evotec Upcoming important dates Financial calendar 2021 Quarterly Statement Q1 2021 Virtual Annual General Meeting 2021 Half-year 2021 Interim Report Quarterly Statement 9M 2021 Virtual Capital Markets Day 11 May 2021 15 June 2021 11 August 2021 11 November 2021 02 December 2021#36evotec WE'D LOVE TO SEE YOU FACE-TO-FACE... e #RESEARCHNEVERSTOPS RIGHT NOW, WE HAVE TO WAIT. We will switch to virtual CAPITAL MARKETS DAY ON 02 DECEMBER 2021#37evotec QUESTIONS AND ANSWERS 3 #RESEARCHNEVERSTOPS#38evotec Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected] #RESEARCHNEVERSTOPS#39evotec Appendix#40in € m evotec 481.9 31 December 2020 PAGE 39 41.1 Operating cash flow Plenty of headroom despite significant capex & equity invested Liquidity bridge H1 2021 -47.2 Capex J.POD -25.4 Capex All other -13.6 Equity investments 21.7 Bank loans & Promissory note -9.9 Repayment of lease obligation 0.7 F/X difference & Other 449.3 30 June 2021#41100 90 80 70 60 50 40 30 20 10 DSO quarterly and LTM DSO average in days Mar 2017 evotec PAGE 40 Jun 2017 Sep 2017 Dec 2017 Mar 2018 Further improvement of accounts receivables management Days Sales Outstanding comfortably within target range Jun 2018 Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 DSO in days quarterly "BMS effect" Dec 2020 Mar 2021 Jun 2021 • Trade accounts receivables including receivables from associated companies decreased to € 79.8m (Dec 2020: € 87.9m) • Days Sales Outstanding (DSO) of 53 comfortably within target range of 50-60 days • Effect from extension of alliance with BMS in protein degradation at the end of Q1 mitigated in Q2 as planned • Reduction of DSO by 27 days versus Q2 2020#42evotec Our employees and potential recruits Creating environment that makes people thrive and strengthens commitment Resilient business model Invest in future, but financial stability in present Principles for Responsible Investment We comply with long-term, sustainable investment criteria PAGE 41 Our purpose is to go VERY long as ONE - #researchneverstops Sustainable thinking is holistic and ensures long-term success AQUALITY EDUCATION DECENT WORK AND ECONOMIC GROWTH GENDER EQUALITY RESPONSIBLE CONSUMPTION AND PRODUCTION GO People Profitability Partners Purpose #RESEARCHNEVERSTOPS PRI Planet Patients Co-ownership We offer > 800 partners an integrated platform and share values of highest integrity Cure all We will not stop until all existing diseases can be cured or at least be better treated We focus on precise, patient-centric medicine Climate leadership Full protection of planet in line with climate science CLEAN WATER AND SANITATION 13 CLIMATE ACTION INDUSTRY INNOVATION AND INFRASTRUCTURE GOOD HEALTH AND WELL-BEING Wo RESPONSIBLE 12 CONSUMPTION 15 AND PRODUCTION ON LAND